Lv7
3920 积分 2022-06-22 加入
SO-7 Efficacy and safety of transarterial chemoembolization (TACE) plus apatinib as compared with TACE alone for recurrent hepatocellular carcinoma: A prospective randomized controlled trial
20天前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
27天前
已完结
“Hepatocellular carcinoma: A life-threatening disease”
27天前
已完结
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
1个月前
已完结
Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma
1个月前
已完结
Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study
1个月前
已完结
Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
4个月前
已关闭
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
4个月前
已完结
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
4个月前
已完结
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
4个月前
已完结
皖公网安备34019202002308
